Navigation Links
Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib,Combination Studies

l results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety, and intended utilization of Cyclacel's product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, the risk that Cyclacel will not obtain approval to market its products, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. These factors and others are more fully discussed under "Risk Factors" in the registration statement on Forms 10-K and in the other reports of Cyclacel filed with the SEC.

Contact

Cyclacel Pharmaceuticals, Inc.
For Investors:
TS Communications Group, LLC
Tara Spiess, 914-921-5900
or
For Media:
Feinstein Kean Healthcare
Heather McDonald, 617-577-8110


'"/>




Page: 1 2 3

Related medicine technology :

1. Cyclacel Pharmaceuticals to Report Sapacitabine Phase I Study Results at the American Society of Clinical Oncology Annual Meeting
2. Cyclacel Pharmaceuticals to Present Preclinical Data on Sapacitabine and Seliciclib at AACR
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
Post Your Comments:
(Date:10/6/2008)...oncept of Other Product - Company,s Bioabsorbable ... HONG KONG, Oct. 6 /- Data from mult...ing stent, OrbusNeich,s Genous Bio-engineered R,st...ter Cardiovascular,Therapeutics symposium, TCT 200...Ph.D., of the Academic Medical Center in,Amsterdam...
(Date:10/3/2008)...IK, Iceland, Oct. 3 /- deCO...iling of an investigational new drug,(IND) applica... modulator,of phosphodiesterase 4 (PDE4), with the...nd is being developed as a new and potentially saf...nd cognitive deficits associated,with Alzheimer,s ...
(Date:10/2/2008)...October 2 /- Pharmaleads has obtained...horization to perform a single,ascending dose Phas...eatment of neuropathic pain., Neuropathic pain is...,prevalence in the world,s population of up to 6%,...auses such as shingles, herpes, diabetes,antivira...
(Date:10/2/2008)... England, October 2 /- Circassia Ltd,...the fields of allergy and critical,care, today ann...udy of its,ToleroMune(R) technology in the field o...s achieved in an earlier phase II study, which dem...oleroMune approach to allergy,desensitization., I...
Breaking Medicine Technology:Data From Multiple Clinical Trials of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2008 2Data From Multiple Clinical Trials of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2008 3deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 2deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 3deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 4deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 5Pharmaleads' Lead Candidate for Pain, PL37, Enters Phase I 2Circassia Initiates Further Phase II Clinical Study of Toleromune(R) Anti-Allergy Technology 2Navitas Opens Cancer Rehabilitation Center in Denver in Conjunction With Presbyterian St Lukes Medical Center 7646 1Navitas Opens Cancer Rehabilitation Center in Denver in Conjunction With Presbyterian St Lukes Medical Center 7646 2Navitas Opens Cancer Rehabilitation Center in Denver in Conjunction With Presbyterian St Lukes Medical Center 7646 3New study finds biodiversity conservation secures ecosystem services for people 1471 1New study finds biodiversity conservation secures ecosystem services for people 1471 2Atomic bomb survivor scientists mark 60 years of long term radiation study 1470 1Atomic bomb survivor scientists mark 60 years of long term radiation study 1470 2CME LLC Restructures Announces Its New Executive Management Team 2074 1CME LLC Restructures Announces Its New Executive Management Team 2074 2
(Date:10/6/2008)... LearnCDHC, a Web-based resource de...r-directed healthcare (CDHC) options including Hea...Accounts (HRAs) and Flexible Spending Accounts (FS...ia, to offer enterprise level services in concert ...dsize business model. , ...
(Date:10/6/2008)...ober 10th, military personnel and their family mem...rson self-assessments, BOSTON, Oct. 6 /PRNewswire...es to Service members and their families that are ...e not. In some instances matters get,worse and one... such times,it is wise to check things out to see ...
(Date:10/6/2008)... results from two Phase 3 studies presented at the...tific Meeting (ACG) in Orlando, Fla., demonstrated...han lansoprazole among patients with more severe g...nes dexlansoprazole with a Dual Delayed Release (D...releases of drug for extended duration of acid sup...
(Date:10/6/2008)...RSEY, Oct. 6 /PRNewswire/ -- The organizers of Inf...nference on Global Sourcing for the,Pharmaceutical... the,Princeton Marriott in New Jersey USA., The c... CEO of the,Global Sourcing Council, and boasts an...ding the likes of Johnson & Johnson, Bristol Myers...
Breaking Medicine News(10 mins):Health News: LearnCDHC Bridges Education Gap on Consumer Directed Healthcare : Interactive Web resource engages and educates consumers about consumer-directed healthcare 2Health News: LearnCDHC Bridges Education Gap on Consumer Directed Healthcare : Interactive Web resource engages and educates consumers about consumer-directed healthcare 3Health News:Many Military Installations Worldwide Participate in National Depression Screening Day 2Health News:Many Military Installations Worldwide Participate in National Depression Screening Day 3Health News:Takeda's investigational PPI TAK-390MR demonstrated higher healing rates compared to lansoprazole 2Health News:Global Sourcing Strategies for the Pharmaceutical Industry 10th - 11th November, Marriott Princeton, New Jersey USA 2
...n tried to quell fears of a pandemic by saying the...is country // , is now under control. "The situa...onitor it closely," Erdogan newsmen with visiting ...i. "So for the time being any danger is out of the...
...tralia. An elderly woman died on 8th January at th...om advance stage of cancer // . She was tested pos...nfusion among the health care officials in Austral...was admitted in the Adelaide hospital and for canc...
... leading cancers in the world today. The problem i... thus the treatment, which includes radiation and ...f tissue leading to disfigurement. Now two Virgin...th the American Dental Association (ADA) to build ...
...Arizona State University have successfully produce...hers were able to produce vaccines from bioenginee...t guinea pigs which were exposed to pneumonic plag...ical trial of the new vaccine in human to study th...
Other Medicine News:Health News:Turkish PM says bird flu under control 2Health News:Tobacco plant based Vaccine against Plague 2
Suture retriever forceps
Knot pusher/suture retriever
Single step suture passage is made simple with Arthro-Pierce instruments. The low profile, highly sharpened tip allows easy passage through tissue in order to retrieve or apply suture.
Arthrex has the most extensive offering of arthroscopic suture passing instruments,available anywhere in the world. We have speci? cally designed the function of our,instruments to work hand in hand
Medicine Products: